To my surprise, there’s been an almost deathly silence about the new, experimental “differential pricing” strategy for GlaxoSmithKline pharmaceuticals that the Financial Times reported on last week. If you didn’t see the story, click here to get the scoop.
As far as I am aware, GSK hasn’t commented publicly on this story at all, and that may [...]
Filed under: Health and drug costs, health economics | Comments Off
